Glenmark Pharmaceuticals Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹3,771Cr
- +15.8% YoY
- −3.3% QoQ
- Net profit
- ₹301Cr
- +7425% YoY
- −25.3% QoQ
- Margin
- 20%
- +3 pp YoY
- −2 pp QoQ
Guidance rank: #49 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
The short version
Future growth expectations for Glenmark Pharmaceuticals are as follows: - FY27 revenue guidance targets between INR 17,000 crores to INR 18,000 crores with an EBITDA margin of 21-22%. Glenmark expects a strong FY27 with revenue guidance of INR 17,000 to 18,000 crores and an EBITDA margin of 21% to 22%, considering growth investments and geopolitical factors.
From Glenmark Pharma.'s Q4 FY26 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
2 more points from Glenmark Pharma.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Glenmark Pharma. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Glenmark has set aside $70 million for future spend related to IGI (Innovative Generics & Injectables) pipeline.
- R&D expenditure is planned at 7% to 8% of sales to support innovation and growth drivers.
- Capital allocation for FY27 is largely focused on expansion of core businesses, including therapeutic areas like respiratory, dermatology, oncology, and branded generics.
- FY26 capex included significant intangible assets additions (~INR 800 crores) due to upfront payments and milestones related to strategic in-licensing and partnerships for innovative business and U.S. injectables.
- From FY27 onwards, capex is expected to normalize around INR 900 crores, reflecting a return to more typical investment levels.
2 more points from Glenmark Pharma.'s call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Glenmark Pharma. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Glenmark Pharma.'s call on order book
Create a free account to keep reading this call
Glenmark Pharma. — Quarterly revenue & net profit
Glenmark Pharma. Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 3,771 | 3,256 | +15.8% | 3,901 | -3.3% |
| Operating profit (EBITDA) | 763 | 561 | +36% | 870 | -12.3% |
| Operating margin | 20% | 17% | +3 pp | 22% | -2 pp |
| Profit before tax | 388 | 8 | +4750% | 534 | -27.3% |
| Net profit (PAT) | 301 | 4 | +7425% | 403 | -25.3% |
| EPS (₹) | 10.68 | 0.16 | +6575% | 14.29 | -25.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹4.2K Cr, net profit ₹264 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Glenmark Pharmaceuticals's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Glenmark Pharma. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Glenmark Pharma. Q4 FY26 results?
Future growth expectations for Glenmark Pharmaceuticals are as follows: - FY27 revenue guidance targets between INR 17,000 crores to INR 18,000 crores with an EBITDA margin of 21-22%. Glenmark expects a strong FY27 with revenue guidance of INR 17,000 to 18,000 crores and an EBITDA margin of 21% to 22%, considering growth investments and geopolitical factors.
What is Glenmark Pharma. share price analysis?
Glenmark Pharma. currently shows a neutral. The stock trades at a P/E of 22.1 with a market cap of ₹69,072 Cr. Investors should review the full earnings analysis for detailed insights.
Is Glenmark Pharma. planning capital expenditure?
Glenmark has set aside $70 million for future spend related to IGI (Innovative Generics & Injectables) pipeline. - R&D expenditure is planned at 7% to 8% of sales to support innovation and growth drivers. - Capital allocation for FY27 is largely focused on expansion of core businesses, including therapeutic areas like respiratory, dermatology, oncology, and branded generics. - FY26 capex included significant intangible assets additions (~INR 800 crores) due to upfront payments and milestones related to strategic in-licensing and partnerships for innovative business and U.S.
Keep Glenmark Pharma. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
